A recorded SCI Connections webinar with Jerrod Kerr, President of the North American Spinal Cord Injury Consortium (NASCIC), and Ian Burkhart, past President of NASCIC, on the outcomes of the September 29 spinal cord injury (SCI) Externally Led Patient-Focused Drug Development (EL-PFDD) meeting: what the community told the U.S. Food and Drug Administration (FDA), what happens with that input next, and what it means for SCI research and treatment.
This SCI Connections webinar from NASCIC was recorded on Wednesday, October 21, 2026. Jerrod Kerr and Ian Burkhart guide you through the outcomes of the September 29 SCI EL-PFDD meeting: what the community told the FDA, what happens with that input next, and what it means for spinal cord injury research and treatment.
The SCI PFDD meeting gathered comments from the SCI community to help the FDA and medical product developers understand what matters most to the spinal cord injury community. The meeting has ended, and the public comment period stays open through October 30, 2026.
The webinar was held on October 21, 2026. The full recording is available on this page, free to watch.

President, NASCIC

Advocate and Neurotechnology Innovator
Ian Burkhart is a C5 tetraplegic, advocate, and neurotechnology innovator. He is the past President of the North American Spinal Cord Injury Consortium, where he championed research, technology, and policies that center on lived experience and drive meaningful improvements in health, independence, and quality of life for people with spinal cord injuries.
The outcomes of the September 29 SCI EL-PFDD meeting: what people living with SCI and their caregivers told the FDA.
Where the community's input goes from here and what comes next after the meeting.
What the meeting means for spinal cord injury research and treatment.
Hear what the SCI community told the FDA on September 29 and what happens with that input next.
Hear how the meeting outcomes relate to the treatments and research that affect the people you care for.
Hear what the community's input to the FDA means for spinal cord injury research and treatment.
The SCI PFDD meeting was held on September 29, 2026. The meeting recording and the public comment form (comment period closes October 30, 2026) are on the SCI PFDD website. The FDA publishes its Patient-Focused Drug Development guidance series online.
Trouble seeing the video? Watch the recording on YouTube.